Skip to main content

FDA Approvals

FDA Approvals, Payers' Guide
Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Fycompa (Perampanel Hydrate) Receives Expanded Indication for Primary Generalized Tonic-Clonic Seizures
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia
Lisa A. Raedler, PhD, RPh
Read More
Page 37 of 53
Results 361 - 370 of 525